Company intelligence / Profile preview

OPM Biosciences

Shanghai, China

Ownership: Private
Employees: ~328
Development stage: Other

Overview

OPM Biosciences’ cell culture media and CDMO services are used by over 200 clinical therapeutics programs globally, supporting biotech and pharmaceutical customers across early development to commercial manufacturing

Modalities: Cell culture mediaVaccineGene therapySmall moleculeMonoclonal antibody
Industry: Contract Manufacturing Organization

Partnerships

Collaborations with over 1000 biotech, pharma, and research customers globally (specific names not listed)

Beyond the preview

Go deeper on OPM Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPM Biosciences.

Explore the full profile